Archives of Dermatological Research

, Volume 279, Issue 1, pp 3–7 | Cite as

Cold-induced Raynaud's phenomenon ameliorated by intravenous administration of ketanserin: a double-blind cross-over study

  • H. Baart de la Faille
  • H. van Weelden
  • J. D. Banga
  • R. G. van Kesteren
Original Contributions
Received:

Summary

Fifteen patients suffering from Raynaud's phenomenon (RP) were exmined. They were placed in a “climate, chamber” (a small room in which the temperature and humidity could be varied). The temperature was gradually decreased, while the humidity was kept constant. After 60–90 min, distinct RP was induced and intravenous medication was administered. The whole trial was performed in a double-blind, crossover fashion. Every patient participated in two experiments performed 2 days apart. Either ketanserin or placebo was given during the first experiment. In the second experiment, the medication (or placebo) which had not been given was administered. The effects of ketanserin were highly significant: the bluish pallor changed into bright erythema and the skin temperature rose significantly. This was interpreted as a spasmolytic effect. Intravenously administered ketanserin has a place in the clinical treatment of acutely deteriorating RP of diverse etiologies.

Key words

Raynaud's phenomenon Ketanserin Serotonin 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bounameaux HM, Hellemans R, Verhaeghe R (1984) Ketanserin (5-HT2-antagonist) in secondary Raynaud's phenomenon. Letter to the editors. J Cardiovasc Pharmacol 6:975–976PubMedGoogle Scholar
  2. 2.
    Coffman JD, Tudor Davies W (1975) Vasospastic diseases: a review. Cardiovasc Dis 18:123–146CrossRefGoogle Scholar
  3. 3.
    Dowd PM, Martin MFR, Cooke ED (1982) Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermat 106:81–89Google Scholar
  4. 4.
    Downey JA, Frewin D (1973) The effect of cold on blood flow in the hands of patients with Raynaud's phenomenon. Clin Sci 44:279–289PubMedGoogle Scholar
  5. 5.
    Editorial (1980) Pathophysiology of Raynaud's phenomenon. Br Med J 281:1027–1028Google Scholar
  6. 6.
    Greaves MW (1982) Prostaglandine, Leukotriene, anti-inflammatoire Substanzen und deren Bedeutung bei entzündlichen Reaktionen der Haut. Hautarzt 33:123–129PubMedGoogle Scholar
  7. 7.
    Halpern A, Kuhn PH, Shaftel HE (1960) Raynaud's disease. Raynaud's phenomenon and serotonin. Angiology 11: 151–167PubMedGoogle Scholar
  8. 8.
    Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biological active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994–2998PubMedGoogle Scholar
  9. 9.
    Jageneau AHM, Hörig Ch, Loots W, Symoens J (1980) Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and a specific antagonist. Angiology 31:828–832PubMedGoogle Scholar
  10. 10.
    Kontos HA, Wasserman AJ (1969) Effect of reserpine in Raynaud's phenomenon. Circulation 39:259–266PubMedGoogle Scholar
  11. 11.
    Le Roy EC (1982) Pathogenesis of seleroderma (systemic sclerosis). J Invest Dermatol 79 [Suppl 1]:87s-89sCrossRefPubMedGoogle Scholar
  12. 12.
    Lewis T (1929) Experiments relating to the peripheral mechanism involved in spasmodic arrest of thecirculation in the fingers. A variety of Raynaud's disease. Heart 15:7–101Google Scholar
  13. 13.
    Moulds, RFW, Iwanov V, Medcalf RL (1984) The effects of platelet derived contractile, agents on human digital arteries. Clin Sci 66:443–451PubMedGoogle Scholar
  14. 14.
    Nueten JM van, Janssen PAJ, Beek J van (1981) Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther 218:217–230PubMedGoogle Scholar
  15. 15.
    Nueten JM van, Leysen JE, Clerk F de (1984) Serotonergic receptor subtypes and vascular reactivity. J Cardiovasc Pharmacol 6 [Suppl 4]:s564-s574PubMedGoogle Scholar
  16. 16.
    Peacock JH (1959) Peripheral venous blood concentration of epinephrine and norepinephrine in primary Raynaud's disease. Circ Res 7:821–827PubMedGoogle Scholar
  17. 17.
    Peroutka SJ (1984) Vascular serotonin receptors, correlation with 5-HT1 and 5-HT2 binding sites (commentary). Biochem Pharmacol 33:2349–2353CrossRefPubMedGoogle Scholar
  18. 18.
    Seibold JR, Jageneau AHM (1984) Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of serotonin (5-HT2) receptor. Arthritis Rheum 27:139–146PubMedGoogle Scholar
  19. 19.
    Stranden E, Roald OK, Krohg K (1982) Treatment of Raynaud's phenomenon with the 5-HT2 receptor antagonist ketanserin. Br Med J 285:1069–1071Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • H. Baart de la Faille
    • 1
  • H. van Weelden
    • 1
  • J. D. Banga
    • 2
  • R. G. van Kesteren
    • 2
  1. 1.Department of DermatologyUniversity Hospital UtrechtUtrechtThe Netherlands
  2. 2.Department of Internal MedicineUniversity Hospital UtrechtUtrechtThe Netherlands

Personalised recommendations